Published in Vaccine Weekly, May 21st, 2003
"Acute lymphoblastic leukemia (ALL) represents the most frequent malignant disease in childhood and adolescence and offers a good prognosis with approximately 80% survival in first remission after polychemotherapy and radiotherapy. In addition, many children with relapsed or refractory ALL will still be cured by allogeneic hematopoietic stem cell transplantation (alloHSCT). However, therapeutic options are limited with a very poor prognosis in case of another relapse after alloHSCT," scientists in Germany report.
"Here, immunotherapy strategies offer a promising alternative to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly